Thursday, October 8, 2026
Via News Knowledge File

Dow Jones Industrial Average

organization80% conf.·synced Aug 13, 2026

US stock market index

49
sourced metrics
68
relationships
2
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Monthly Return
0percent
Nov 30, 2026⚠ sources conflictsource
Distance From Record Close
3percent
Apr 15, 2026source
Year To Date Return
0.3percent
Apr 10, 2026source
Daily Return
0.58percent
Apr 10, 2026source
Index Level
47909.92points
Apr 8, 2026source
Daily Change
-0.13percent
Apr 3, 2026source
Daily Change Percent
0.48percent
Apr 2, 2026source
Daily Change Points
1000index_points
Mar 31, 2026source
Correction Depth
-10percent
Mar 28, 2026source
Ytd Performance
-6.0percent
Mar 27, 2026source
Weekly Performance
-1.7percent
Mar 27, 2026source
Drawdown From Peak
-10percent
Mar 27, 2026source
Drawdown From High
7.9percent
Mar 27, 2026source
Index Value
-0.81percent
Mar 27, 2026source
Percent Change
-1.0percent
Mar 27, 2026source
Decline Since Iran War
-7percent
Mar 27, 2026source
Closing Price
45960.11points
Mar 26, 2026source
Drawdown From Ath
-7.9percent
Mar 26, 2026source

Stated objectives

Reach 50,000 points

source
target: 50000 stated

Reach 50,000 milestone

source
target: 50000 points stated

Relationship graph · 68 connections

Competes with
16
Covered by
11
located in
11
subsidiary of
8
regulates
5
component of
5
licensed from
2
Member of
2

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com